|
A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis Clinical research trials and A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis. A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis clinical trial. Human subjects often obtain the finest healthcare possible for their A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis  A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis
A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis
For Condition: Rheumatoid Arthritis
Status: Completed
Sponsor(s): Bristol-Myers Squibb ,
Synopsis: The purpose of this clinical research study is to learn if BMS-188667 is safe when co-administered with other approved rheumatoid arthritis medications.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Meet criteria of American Rheumatism Association for the diagnosis of rheumatoid arthritis and the American College of Rheumatology functional classes I, II III or IV - Subjects must be taking 1 or more DMARDs and/or biologic approved for RA for at least 3 months and be on a stable dose for 28 days prior to Day 1. Exclusion: - Other auto-immune disease as a main diagnosis (e.g. SLE, Scleroderma) - Active TB requiring Rx within last 3 years
Total Enrollment:
Location and Contact Information:
Local Institution
Wyomissing, Pennsylvania,
United States
Local Institution
Milwaukee, Wisconsin,
United States
Local Institution
Hickory, North Carolina,
United States
Local Institution
Decatur, Alabama,
United States
Local Institution
Westminster, Maryland,
United States
Local Institution
Indianapolis, Indiana,
United States
Local Institution
Louisville, Kentucky,
United States
Local Institution
Cumberland, Maryland,
United States
Local Institution
Columbia, South Carolina,
United States
Local Institution
Baltimore, Maryland,
United States
Local Institution
San Francisco, California,
United States
Local Institution
Cleveland, Ohio,
United States
Local Institution
Richmond, Virginia,
United States
Local Institution
Olympia, Washington,
United States
Local Institution
Paradise, Arizona,
United States
Local Institution
Hamden, Connecticut,
United States
Local Institution
Lake Worth, Florida,
United States
Local Institution
Canton, Ohio,
United States
Local Institution
Sioux Falls, South Dakota,
United States
Local Institution
Tucson, Arizona,
United States
Local Institution
Chicago, Illinois,
United States
Local Instituton
Durham, North Carolina,
United States
Local Institution
Youngstown, Ohio,
United States
Local Institution
Blairsville, Georgia,
United States
Local Institution
Tacoma, Washington,
United States
Local Institution
Columbus, Ohio,
United States
Local Institution
Phoenix, Arizona,
United States
Local Institution
Loveland, Colorado,
United States
Local Institution
Toms River, New Jersey,
United States
Local Institution
New Orleans, Louisiana,
United States
Local Institution
New York City, New York,
United States
Local Institution
Largo, Florida,
United States
Local Institution
Los Alamos, New Mexico,
United States
Local Institution
Oklahoma City, Oklahoma,
United States
Local Institution
Elyria, Ohio,
United States
Local Institution
Grand Rapids, Michigan,
United States
Local Institution
Nashville, Tennessee,
United States
Local Institution
Ducktown, Tennessee,
United States
Local Institution
Menomonee Falls, Wisconsin,
United States
Local Institution
Royal Oak, Michigan,
United States
Local Institution
Evansville, Indiana,
United States
Local Institution
Wichita, Kansas,
United States
Local Institution
Boston, Massachusetts,
United States
Local Institution
Edmonds, Washington,
United States
Additional Information:
Study ID Numbers: IM101-031;
Study Start Date:
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00048932
Other Rheumatoid Arthritis Studies:
1. The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women with Rheumatoid Arthritis and the Effect of Treatment with Etanercept
2. Trial with HuMax-CD4 in Patients with Rheumatoid Arthritis failing treatment with Methotrexate and a TNF-alpha blocker.
3. Long term safety and tolerability of an investigational drug in patients with rheumatoid arthritis
4. Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients with Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate
5. Efficacy and Safety of Investigational Drug in Patients with Rheumatoid Arthritis Who Failed at Least One DMARD (Disease Modifying Anti-Rheumatic Drug)
Related Studies:
Other Rheumatoid Arthritis Clinical Trials
Other Tennessee Clinical Trials
Other Ducktown Clinical Trials
A Phase III study of BMS-188667 in subjects with active rheumatoid arthritis
|
|
|
|
|
|
|
|
